Coronary In-Stent Restenosis: JACC State-of-the-Art Review

J Am Coll Cardiol. 2022 Jul 26;80(4):348-372. doi: 10.1016/j.jacc.2022.05.017.

Abstract

The introduction and subsequent iterations of drug-eluting stent technologies have substantially improved the efficacy and safety of percutaneous coronary interventions. However, the incidence of in-stent restenosis (ISR) and the resultant need for repeated revascularization still occur at a rate of 1%-2% per year. Given that millions of drug-eluting stents are implanted each year around the globe, ISR can be considered as a pathologic entity of public health significance. The mechanisms of ISR are multifactorial. Since the first description of the angiographic patterns of ISR, the advent of intracoronary imaging has further elucidated the mechanisms and patterns of ISR. The armamentarium and treatment strategies of ISR have also evolved over time. Currently, an individualized approach using intracoronary imaging to characterize the underlying substrate of ISR is recommended. In this paper, we comprehensively reviewed the incidence, mechanisms, and imaging characterization of ISR and propose a contemporary treatment algorithm.

Keywords: coronary artery disease; drug-eluting stent; in-stent restenosis; revascularization.

Publication types

  • Review

MeSH terms

  • Coronary Angiography / adverse effects
  • Coronary Restenosis* / diagnostic imaging
  • Coronary Restenosis* / epidemiology
  • Drug-Eluting Stents* / adverse effects
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects
  • Risk Factors
  • Stents / adverse effects
  • Treatment Outcome